Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00074776 · ClinicalTrials.gov registry record · Phase 3

Acute Treatment of Bipolar II Depression

A Phase 3 study of Bipolar Disorder, sponsored by Stanford University.

Completed
Registry status
Phase 3
Development phase
102
Enrollment target
1
Study location

NCT00074776 is a Phase 3 study of Bipolar Disorder that has completed, run by Stanford University. The registered enrollment target is 102 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00074776, a Phase 3 study of Bipolar Disorder, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 3
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.

Conditions Studied

Interventions

  • DRUG Lamotrigine
  • DRUG Lithium

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center at Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2003-05
Est. Completion 2007-10
Phase Phase 3

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT00074776

The ClinicalTrials.gov registry entry for NCT00074776 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (69% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Lamotrigine is the first listed.

NCT00074776 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00074776 about?

NCT00074776 is a clinical study titled "Acute Treatment of Bipolar II Depression". This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.

What is the current status of trial NCT00074776?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2003-05. Estimated completion is 2007-10.

What conditions does trial NCT00074776 study?

This clinical trial studies the following conditions: Bipolar Disorder.

What interventions are being tested in trial NCT00074776?

The interventions under investigation include: Lamotrigine (DRUG), Lithium (DRUG).

Who is sponsoring clinical trial NCT00074776?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00074776 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.